Fortrea Securities Class Action Lawsuit
Analysis based on 8 articles · First reported Jun 06, 2025 · Last updated Jul 06, 2025
The market is negatively impacted by the alleged misleading statements from Fortrea, leading to significant stock price declines. The ongoing class action lawsuit against Fortrea creates uncertainty for investors and highlights potential risks in the biotechnology and pharmaceutical contract research organization sector.
Faruqi & Faruqi, a national securities law firm, is investigating Fortrea Holdings Inc. and encouraging investors to join a federal securities class action lawsuit. The complaint alleges that Fortrea made false and misleading statements between July 3, 2023, and February 28, 2025. Specifically, Fortrea is accused of overestimating revenue from Pre-Spin Projects, overstating cost savings from exiting TSAs, inflating 2025 EBITDA targets, and overstating the viability of its post-Spin-Off business model. These alleged misrepresentations led to significant drops in Fortrea's stock price following downgrades by Jefferies and EITC, and the announcement of disappointing Q4 and full-year 2024 financial results.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard